COO

Business profile & competitive position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically in Medical - Instruments & Supplies. Its business is split into two global medical-device segments: CooperVision, which develops, manufactures and markets single-use, two-week and monthly contact lenses plus specialty eyecare products; and CooperSurgical, which supplies more than 600 products and services in fertility and women’s health. CooperVision’s portfolio includes silicone hydrogel lenses, orthokeratology and scleral lenses, while its MiSight 1 day lens is the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to both correct and slow myopia progression in age-appropriate children. CooperSurgical covers gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products are sold in over 130 countries and the company estimates they touch more than fifty million lives each year.

Margin and return figures temper the bullish growth narrative. The net margin is 5.6% and ROE is 2.8%, both relatively modest for a company with leading product positions. Those numbers imply durable business scale but not necessarily strong pricing power or capital-light returns. A medical-device business usually carries high fixed costs, long regulatory cycles, heavy marketing to eye-care practitioners and clinicians, and ongoing quality-assurance investment. The modest 2.8% ROE can reflect capital intensity, product-line transitions, or spending ahead of revenue, especially in newer areas such as myopia management and fertility services. The regulatory exclusivity around MiSight is therefore a meaningful differentiator, yet the overall profit conversion remains muted in the data provided.

Financial posture

With a market capitalization of $14.8B and a trailing P/E of 64.1, Cooper Companies is priced for substantial future growth rather than current earnings power. The 5.6% net margin and 2.8% ROE stand in sharp contrast to that valuation multiple: a P/E in the mid-60s normally assumes earnings can expand considerably or that the market views the company as a defensive, high-quality compounder. The beta of 0.82 supports the defensive interpretation relative to the broader market, but the combination of high valuation and low returns on equity means the stock’s direction will likely hinge on whether management can convert strategic investments into margin expansion. There is no debt figure included here, so balance-sheet risk cannot be judged from the present data.

Strategic priorities & outlook

The company’s most recent 10-K filing frames its operational priorities around deepening penetration and geographic reach. CooperVision aims for greater worldwide market penetration of recently introduced products and plans to expand its presence in both existing and emerging markets. It is also increasing investment in distribution and packaging capabilities to support growth and service quality. A parallel priority is developing the myopia-management market through education of eye-care practitioners, patients and families, suggesting this category is still in the opening stages of commercialization. Meanwhile, CooperSurgical expects to keep investing, including through strategic transactions, to build out its integrated solutions model across fertility and women’s health. About 500 employees work in research and development across both segments, underscoring that product pipeline investment is central to the company’s thesis.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company, Cooper Companies faces the macro and geopolitical exposures typical of the global device industry. Regulation is a core variable: FDA, Chinese and Japanese approvals are explicitly part of the MiSight story, and shifts in regulatory timelines or reimbursement rules in any major market could alter the value of new product launches. Currency risk matters because products reach over 130 countries; a weaker euro, yen or emerging-market currency against the dollar would compress reported revenue and earnings. Supply-chain inputs such as silicone hydrogel polymers, packaging materials and sterilization services carry commodity and energy-price sensitivity, while logistics costs can swing with fuel and freight markets. Demographic trends are also structural drivers: rising childhood myopia rates support CooperVision’s myopia-management portfolio, while deferred family formation and assisted-reproductive-technology demand influence CooperSurgical. Finally, trade policy—tariffs on medical goods or country-specific export restrictions—could affect manufacturing economics for a company that sells worldwide.

Recent developments

The available news flow since early August 2026 contains no direct Cooper Companies headlines. The item dated 2026-08-12 from GuruFocus, “Minesto adapts organization to strengthen customer service offering,” involves Minesto, not The Cooper Companies. Similarly, the 2026-08-11 TechCrunch headline “Brad Lightcap, OpenAI's longtime COO, is leaving to ‘start something new’” is unrelated to the stock ticker COO and refers to OpenAI’s chief operating officer. The other two GuruFocus entries dated 2026-08-06 and 2026-08-05 summarize second-quarter 2026 earnings calls for Motorola Solutions and Assurant, respectively. They are useful only as broad market context showing other firms reporting record results and raised guidance, but they carry no direct read-through to Cooper Companies’ operating performance.

Earnings behavior & post-earnings drift

Cooper Companies has delivered an unblemished earnings record over the last eight reported quarters, beating the official estimate in all eight, with an average positive surprise of 4.6%. Yet the post-earnings price reaction has been a修缮 (average 5-day move of -0.91%, classified as downward drift), meaning that beats have often been followed by selling pressure once the initial reaction settles.

The most recent quarters illustrate that tension clearly. On 2026-06-04, the company reported EPS of $1.21 versus the $1.11 estimate, a 10.0% surprise, and the stock rose 8.58% the next day and 8.85% over the following five sessions. On 2026-03-05, EPS was $1.10 versus $1.03, a 6.8% beat, but the stock still fell 4.55% the next day and 10.82% over the next five sessions. On 2025-12-04, EPS of $1.15 beat the $1.11 estimate by 3.6%, driving a 5.67% next-day gain and a 6.59% five-day gain. On 2025-08-27, a 2.8% beat with EPS of $1.10 versus $1.07 produced a 12.86% drop the next day and an 8.24% decline over the next five sessions. The pattern is consistent: the company reliably clears the official bar, but the market’s forward-looking expectations are not always satisfied, and the unofficial consensus may be higher than the published estimate. The next scheduled report is 2026-09-09 after the close, with the consensus EPS estimate at $1.12. As of the current snapshot, the share price is $75.63, above the 50-day EMA of $71.61, with an RSI of 60.9.

Readers seeking a deeper dive should look at the full institutional verdict to contrast these figures with forward guidance, peer valuations, and sector-specific risk assessments.